Acesso livre
Acesso livre

Arquivos do dia: Março 31, 2022

[Preprint] Estudo de coorte retrospectiva | 2º reforço de vacina e mortalidade por Covid-19 em adultos de 60 a 100 anos de idade.

31 Mar, 2022 | 13:44h

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Comentários:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical


EUA aprovam 2ª dose de reforço contra Covid-19 para pessoas de 50 anos de idade ou mais e indivíduos imunocomprometidos.

31 Mar, 2022 | 13:41h

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

Ver diretriz: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration


Estudo de coorte | Desfechos de curto prazo da monoterapia com corticosteroide na síndrome inflamatória multissistêmica em crianças.

31 Mar, 2022 | 13:40h

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

 

Comentário no Twitter

 


Estudo RECOVERY – 2 anos.

31 Mar, 2022 | 13:38h

The RECOVERY Trial – two years on – University of Oxford

Conteúdos relacionados:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Comentário no Twitter

 


Relato de caso | Os danos da antibioticoprofilaxia pós-operatória.

31 Mar, 2022 | 13:36h

The Harms of Postoperative Antibiotic Prophylaxis: A Teachable Moment – JAMA Internal Medicine (gratuito por tempo limitado)


Bacteriemia por S. aureus complicada e não complicada: uma pesquisa internacional Delphi entre especialistas em doenças infecciosas sobre definições e tratamento.

31 Mar, 2022 | 13:34h

Complicated and uncomplicated S. aureus bacteremia: an international Delphi survey among infectious diseases experts on definitions and treatment – Clinical Microbiology and Infection


Posicionamento científico AHA/ASA | Tratamento endovascular e trombólise para AVC isquêmico agudo em pacientes com incapacidade premórbida ou demência.

31 Mar, 2022 | 13:32h

Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association – Stroke

Comunicado de imprensa: Stroke treatments safe and effective for people with existing disability or dementia – American Heart Association

 

Comentário no Twitter (fio – clique para saber mais)

 


Estudo mostra que é comum o excesso de tratamento em pacientes com diabetes tipo 2 residentes em casas de repouso.

31 Mar, 2022 | 13:30h

Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes – Journal of the American Geriatrics Society

Comentários:

Overtreatment of T2DM Common Among VA Nursing Home Residents – HealthDay

Diabetes treatment deintensification uncommon in nursing home residents – medwire News


M-A | Anormalidades do parênquima pulmonar após internação por COVID-19 e pneumonite viral.

31 Mar, 2022 | 13:29h

Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis – Thorax


Análise sistemática para o Global Burden of Disease 2019 Study | Impacto global, regional e nacional de doenças e lesões para adultos de 70 anos de idade ou mais.

31 Mar, 2022 | 13:27h

Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study – The BMJ

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.